PharmaSGP is a pure-play consumer health company with a broad portfolio of leading natural non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are mainly sold through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company’s core brands in the category „Health Brands“ cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic natural pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. The DESEO® and Neradin® brands are aimed at the men’s health market. Since September 2021, the brands Baldriparan®, Formigran®, Spalt® and Kamol® are part of the PharmaSGP portfolio. With the No. 1* herbal sleep aid in Germany Baldriparan®, PharmaSGP expands its portfolio and enters the sleep disorder category. Formigran®, Spalt® and Kamol® expand the product range in the important category "pain therapy".
PharmaSGP has established an asset-light business model that ensures decidedly substantial scalability with a highly efficient cost structure. Years of in-depth regulatory experience make it possible to quickly integrate OTC products of the most diverse categories into the portfolio and launch onto markets. As a D2C specialist, PharmaSGP achieves a very wide coverage among relevant target groups with over 170 million contacts per month – and all this under attractive and efficient media conditions.
Drawing on these strengths, PharmaSGP has been generating continuous and profitable growth of the „Health Brands“ for many years.
PharmaSGP's growth strategy aims to make efficient use of the pan-European platform.
On the one hand, PharmaSGP is constantly expanding the number of indications covered by its product range, while on the other, PharmaSGP is pushing expansion within Europe. Apart from the further organic growth of the existing „Health Brands“, PharmaSGP will focus on the acquisition and integration of established brands in future.
The acquisition of the OTC brand portfolio (Baldriparan®, Formigran®, Spalt® and Kamol®) from the GlaxoSmithKline Group in September 2021 is part of the successful M&A strategy. Strategically, PharmaSGP is strengthening its business by further expanding the "Health Brands" category, extending the therapeutic areas and opening up new markets in Europe. In the future, the SGP Group will also be active in Switzerland, Hungary, Poland, the Czech Republic and Slovakia.
CEO
Peter Gerckens (born 1987) joined PharmaSGP Holding SE as a member of the Executive Board in 2024. Peter has been CEO of PharmaSGP since January 2025 and is responsible for the operational business and the development of the product pipeline with a focus on marketing, research and development, quality assurance and purchasing. Peter started his career in marketing at Procter & Gamble and soon moved to McKinsey's Munich office. There he advised clients on strategic and operational issues for over 8 years, focusing on the consumer goods industry, among others. Before joining SGP, Peter was Managing Director and shareholder of a medium-sized service company in Munich with over 100 employees. There, Peter was responsible for finance, marketing and several business units.
Peter is a business economist and holds a Bachelor's degree (B.A.) from the University of St. Gallen, a Master's degree (M.Sc.) from the London School of Economics as well as an MBA from Harvard Business School.
Further mandates: Wilh. Werhahn KG, Neuss
Michael Rudolf (born 1974) joined the FUTRUE Group in 2016 and has been CFO of PharmaSGP since 2017. Prior to joining PharmaSGP, Michael Rudolf has worked at McKinsey & Company, served as head of mergers & acquisitions, portfolio management and corporate projects at Verlagsgruppe Weltbild, and was responsible for investment and portfolio management for digital investments of the Media-Saturn Group. He is holding a Master’s Degree in Business Administration from the University of Mannheim, Germany.
| Key financial data | 2017* | 2018* | 2019* | 2020* | 2021* | 2022* | 2023* | 2024* | H1 2024** | H1 2025** |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues (€ million) | 53.1 | 60.6 | 62.6 | 63.2 | 65.3 | 85.8 | 101.1 | 118.8 | 58.4 | 66.0 |
| Revenue growth (%)** | – | 14.2 | 3.3 | 1.1 | 3.3 | 31.3 | 17.8 | 17.5 | 17.4 | 13.0 |
| adjusted EBITDA (€ million)**,*** | 15.7 | 19.9 | 22.8 | 17.0 | 19.4 | 28.2 | 34.1 | 37.2 | 16.9 | 16.7 |
| adjusted EBITDA margin (% of revenues)**,*** | 29.7 | 32.9 | 36.5 | 26.9 | 29.7 | 32.9 | 33.7 | 31.3 | 28.9 | 25.3 |
| adjusted EBIT (€ million)**,*** | 15.3 | 19.5 | 22.4 | 16.5 | 15.9 | 19.0 | 24.7 | 27.8 | 12.2 | 11.9 |
| adjusted EBIT margin (% of revenues)**,*** | 28.9 | 32.3 | 35.8 | 26.1 | 24.3 | 22.1 | 24.4 | 23.4 | 20.9 | 18.0 |
| Total shareholders' equity (€ million)**** | 73.7 | 84.4 | 95.6 | 11.5 | 22.2 | 31.1 | 39.8 | 32.0 | 32.6 | 39.2 |
| Balance sheet total (€ million)**** | 84.1 | 92.0 | 103.7 | 24.9 | 115.3 | 129.1 | 131.3 | 114.3 | 134.2 | 115.2 |
| Equity ratio (% of balance sheet total)** | 87.7 | 91.7 | 92.1 | 46.1 | 19.3 | 24.1 | 30.3 | 28.0 | 24.3 | 34.1 |
* Geprüft, soweit nicht anders angegeben.
** Ungeprüft.
*** PharmaSGP bereinigt Kosten unter anderem für die gesellschaftsrechtliche und organisatorische Strukturierung der PharmaSGP Gruppe sowie für Rechts- und Beratungskosten im Zusammenhang mit Akquisitionen.
**** as of 31 December or 30 June
If you have any further questions, please do not hesitate to contact us. You can contact us via e-mail, mail or directly by telephone.
